Background: Breast cancer survivors often face physical and psychological challenges, including weight gain, metabolic syndrome, and reduced quality of life. To address these concerns, a mobile app-based rehabilitation program called “THRIVE” was developed to improve physical activity, medication adherence, and health-related quality of life (HRQoL) in this population.Methods: This prospective, single-arm study assessed the feasibility and effectiveness of the “THRIVE” app among breast cancer survivors undergoing hormonal therapy. Participants were recruited from Queen Mary Hospital in Hong Kong between December 2022 and June 2023. Eligible survivors had completed treatment within the last five years or had stable advanced disease on hormonal therapy. Participants monitored their exercise, medication adherence, and self-care via the app and a Fitbit activity tracker for 16 weeks. Primary outcomes included recruitment, dropout, adherence rates, and safety. Secondary outcomes, measured at baseline and week 16, included physical activity intensity, HRQoL, psychological stress, body composition, and app satisfaction.Results: A total of 50 participants, with a median age of 53 years, completed the study. The recruitment rate was 70.4% with no dropouts. The adherence rate, measured by completing exercises recommended in the mobile app at least three times per week, was 74%. No severe adverse events were reported. While physical activity intensity showed no significant changes from baseline to week 16 (p= 0.24), cognitive function (p= 0.021), future perspective (p= 0.044), arm symptoms (p= 0.042), depression (p= 0.01), and anxiety (p= 0.004) improved. All participants reported perfect medication compliance (100%). Satisfaction with the app was high.Conclusions: This mobile app-based rehabilitation program demonstrated good feasibility, with satisfactory recruitment, adherence, and safety, providing valuable insights into future definitive studies.
背景：乳腺癌幸存者常面临体重增加、代谢综合征及生活质量下降等身心挑战。为应对这些问题，本研究开发了名为"THRIVE"的移动应用程序康复计划，旨在提升该人群的身体活动水平、用药依从性及健康相关生活质量。 方法：这项前瞻性单臂研究评估了"THRIVE"应用程序在接受激素治疗的乳腺癌幸存者中的可行性与有效性。参与者于2022年12月至2023年6月期间从香港玛丽医院招募。符合条件的幸存者需满足以下条件：过去五年内完成治疗，或处于激素治疗稳定的晚期阶段。参与者通过应用程序和Fitbit活动追踪器监测运动、用药依从性及自我护理情况，持续16周。主要观察指标包括招募率、退出率、依从率及安全性。在基线和第16周测量的次要指标包括身体活动强度、健康相关生活质量、心理压力、身体成分及应用程序满意度。 结果：共50名中位年龄53岁的参与者完成研究。招募率达70.4%，无中途退出者。以每周至少完成三次应用程序推荐运动为标准的依从率为74%。未报告严重不良事件。虽然从基线到第16周的身体活动强度未见显著变化（p=0.24），但认知功能（p=0.021）、未来展望（p=0.044）、手臂症状（p=0.042）、抑郁（p=0.01）和焦虑（p=0.004）均得到改善。所有参与者均报告完全遵医嘱用药（100%）。应用程序满意度较高。 结论：该基于移动应用程序的康复计划展现出良好的可行性，在招募、依从性和安全性方面表现令人满意，为未来确定性研究提供了重要参考。
肿瘤(癌症)患者之家